Objective:

To explore the visual and anatomical outcomes of intravitreal hydroxypropylmethylcellulose (HPMC) for treating chronic structural hypotony, emphasizing the innovative approach to treatment.

Key Findings:

• Patients experienced significant visual improvement, with one case improving from 1/60 to 6/12 vision, indicating a substantial recovery.
• The treatment involved injecting viscoelastic into the vitreous cavity, addressing the underlying structural issues that contribute to hypotony.
• The study reports on outcomes for the first eight patients treated over one year, providing initial evidence of the treatment's effectiveness.

Interpretation:

The new approach to treating chronic hypotony shows promise in restoring vision and structural integrity, moving beyond traditional methods that primarily focus on pressure management, which often yield limited results.

Limitations:

• The treatment is off-license, requiring careful oversight and governance, which may limit its immediate applicability.
• The study is based on a small cohort of patients, limiting generalizability and necessitating further research to validate findings.

Conclusion:

This innovative treatment strategy for chronic hypotony may redefine success by prioritizing meaningful visual outcomes and structural restoration, potentially influencing future treatment protocols.